Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancerKevin Lin, Kris C. Wood, Justine C. Rutter et al.|Nature Genetics|2020Cited by 91
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Patrick Auberger et al.|Nature Cancer|2022Cited by 42
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Cancer Discovery|2020Cited by 26
Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader moleculeLoïs Kelly, Alexandre Puissant, Justine C. Rutter et al.|Nature Cancer|2024Cited by 25
Figure S10 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank W. Ling et al.|Unknown|2023Cited by 0